Welcome To Pronia Medical Systems
At Pronia Medical Systems, we utilize technology to improve patient safety and save lives. Intensive glycemic control (maintenance of near normal glucose levels) in critically ill patients has been demonstrated to reduce complications and save lives in patients with and without a known history of diabetes. The physiologic stress associated with critical illness leads to hyperglycemia which has been reliably correlated with increased complications. In the past, intensive care units for the most part ignored blood sugars until the levels were above 200 mg/dl if not higher. Several studies have demonstrated improved outcomes with better glucose control.
However, many recent randomized clinical trials have failed to show a benefit in terms of mortality when a truly normal glucose range (80-110 mg/dl) was targeted (most recently the NICE-SUGAR study) when compared to targets of 180-200 mg/dl. These studies demonstrated an up to 6 fold higher incidence of severe hypoglycemia (<40 mg/dl) in the 80-110 mg/dl target group. This has prompted the American Association of Clinical 
Endocrinology (AACE) and the American Diabetes Association (ADA) to jointly recommend a new target range for critically ill patients of 140-180 mg/dl. The consensus statement also states that “Although strong evidence is lacking, somewhat lower glucose targets may be appropriate in selected patients. Targets less than 110 mg/dL (6.1mmol/L), however, are not recommended. Use of insulin infusion protocols with demonstrated safety and efficacy, resulting in low rates of occurrence of hypoglycemia, is highly recommended.” During a conference at the AACE annual meeting on May 15, 2009 organized to discuss the new Consensus recommendations, the authors of the Consensus statement presented the data utilized to develop their recommendations. When specifically asked about successful currently used protocols with a target of 100-140 mg/dl with very low levels of hypoglycemia, the speakers stated that the Consensus recommendations are designed to be general recommendations for the entire medical community and may not apply to facilities where lower targets are being reached with low incidence of hypoglycemia and demonstrated safety.
The protocols included in the GlucoCare™ IGC System are able to provide excellent control of blood sugars with low rates of hypoglycemia utilizing established protocols that have been demonstrated to be safe. We will continually update our system with the most recent protocols and modify our system rapidly when new scientific data is generated. The NICE-SUGAR <180 mg/dl protocol and a new Yale 120-180 mg/dl target are currently being developed for our system.